Before taking Dayvigo(lemborexant)
Lemborexant is a medication used for treating insomnia, belonging to the class of central nervous system (CNS) inhibitors.
Before taking Dayvigo(lemborexant)
Before use, patients should fully understand the drug's characteristics, side effects, risks, drug interactions, and precautions for special populations, and use it rationally under medical guidance.
1. CNS Depressant Effects and Daytime Impairment
Lemborexant suppresses the CNS, potentially reducing daytime wakefulness even at normal doses, with suppression persisting for days in some patients after discontinuation. Drowsiness may affect driving and other activities requiring high alertness. Risks increase significantly with insufficient sleep or overdose. Concomitant use with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) heightens CNS depression and exacerbates daytime impairment.
2. Sleep Paralysis, Hypnagogic/Hypnopompic Hallucinations, and Cataplexy-like Symptoms
Patients may experience inability to move or speak during sleep-wake transitions, including vivid and disturbing perceptions, which can cause distress.
3. Complex Sleep Behaviors
Complex sleep behaviors like sleepwalking and sleep driving may occur, often without patient memory. Co-administration with alcohol or other CNS depressants increases these risks.
4. Patients with Compromised Respiratory Function
Caution is needed in patients with respiratory impairment (e.g., OSA or COPD), as lemborexant may affect respiratory function.
5. Worsening Depression/Suicidal Ideation
Clinical studies show a higher incidence of suicidal thoughts or behaviors in lemborexant groups versus placebo. Hypnotics in primary depression patients have reported worsening depression and increased suicidal ideation, requiring special monitoring and limited drug supply to prevent intentional overdose.
6. Need for Comorbid Diagnosis Evaluation
Sleep disorders may signal underlying medical or psychiatric conditions, necessitating comprehensive evaluation before treatment. If insomnia persists after 7–10 days, undiagnosed conditions may require further assessment.
Lemborexant for insomnia must be used strictly as prescribed, with attention to the above risks and precautions. Patients should fully understand this information before treatment and maintain close communication with their doctor to adjust the regimen and address issues promptly.
